How Much Does Mounjaro Cost in Illinois in 2026?

Brand-Name Mounjaro Retail Pricing in Illinois

The manufacturer list price set by Eli Lilly for Mounjaro remains $1,023 per month across all dose strengths in 2026. Illinois retail pharmacies (CVS, Walgreens, independent chains) pass through this wholesale acquisition cost with minimal markup, so the average cash-pay price at Illinois counters matches the list figure almost exactly.

This price covers a carton of four single-dose pens, one injection per week. Dose escalation from 2.5 mg up to 15 mg does not change the per-carton price, which means patients on the maximum 15 mg dose pay the same as those on the starting 2.5 mg dose. The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58% versus 0.86% for semaglutide 1 mg at 40 weeks, establishing the clinical value behind these costs 1.

Without insurance or discount programs, a full year of brand Mounjaro costs approximately $12,276 out of pocket. That figure places it among the most expensive chronic medications dispensed at Illinois pharmacies, comparable to other incretin-based therapies like semaglutide (Ozempic/Wegovy).

Illinois Medicaid Coverage for Mounjaro

Illinois Medicaid (managed through the state's HealthChoice Illinois MCOs) covers Mounjaro with prior authorization for the FDA-approved type 2 diabetes indication. The PA process typically requires documentation of: a confirmed type 2 diabetes diagnosis, failure or intolerance of metformin, and a prescribing clinician's attestation that the patient meets metabolic criteria.

Coverage for weight management alone (the obesity indication carries the Zepbound brand name) is not standard under Illinois Medicaid fee-for-service as of early 2026. Some MCO plans may cover off-label use on a case-by-case basis, but approvals remain inconsistent.

The Illinois Department of Healthcare and Family Services (HFS) publishes its preferred drug list quarterly. Tirzepatide appears on the list under non-preferred GLP-1/GIP receptor agonists, meaning step therapy through a preferred agent (often dulaglutide or semaglutide) may be required before approval 2. Providers should submit clinical documentation showing inadequate glycemic control on the preferred agent to expedite PA turnaround, which typically takes 48 to 72 hours through electronic prior authorization systems used by Illinois MCOs.

Commercial Insurance Coverage in Illinois

Most large commercial insurers operating in Illinois (Blue Cross Blue Shield of Illinois, UnitedHealthcare, Aetna, Cigna, Humana) include tirzepatide on their formularies for type 2 diabetes. Coverage structures vary significantly.

Typical tier placement: Mounjaro sits on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty) depending on the plan. Tier 3 copays in Illinois PPO plans average $60 to $150 per fill. Tier 4 or specialty-tier placement can push the patient responsibility to 25-33% coinsurance, translating to $250 to $340 monthly before any manufacturer assistance.

Prior authorization requirements are near-universal. Illinois commercial plans generally require:

• Confirmed A1c of 7.0% or higher on current therapy
• Trial of at least one preferred GLP-1 RA (often semaglutide or dulaglutide) for 90 days
• BMI documentation (some plans waive step therapy if BMI exceeds 35 with comorbidities)

The Endocrine Society's 2023 guidelines recommend GLP-1 or dual GIP/GLP-1 receptor agonists as second-line therapy after metformin in patients with type 2 diabetes and overweight/obesity, providing clinical justification for PA appeals 3.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, stated in a 2023 commentary: "Tirzepatide represents a meaningful advance in dual-hormone targeting, and access barriers including prior authorization create clinically significant treatment delays for patients who would benefit most."

The Eli Lilly Savings Card in Illinois

Eli Lilly's Mounjaro Savings Card program operates in Illinois and can reduce commercially insured patient copays to as low as $25 per monthly fill. The card covers up to $573 in copay/coinsurance costs per fill, with a maximum annual benefit of approximately $3,400.

Eligibility requirements:

• Must have commercial (private) insurance that covers Mounjaro
• Cannot be enrolled in Medicare, Medicaid, Tricare, or other government-funded programs
• Must be a resident of the United States (Illinois qualifies)
• No income requirements

Patients activate the card through the Mounjaro.com portal or by calling Lilly's patient services line. The card functions as a secondary payer at the pharmacy counter. Illinois pharmacists process the primary insurance claim first, then run the savings card as a secondary BIN/PCN to reduce the remaining patient responsibility.

One limitation: if a patient's insurance denies Mounjaro entirely (not just places it at a high copay), the savings card does not apply. The card only offsets cost-sharing on approved claims. For patients receiving coverage denials, a formal appeal or formulary exception request must succeed before the savings card becomes usable 4.

Compounded Tirzepatide in Illinois: Legality and Pricing

Compounded tirzepatide is available in Illinois through licensed 503A compounding pharmacies. These pharmacies operate under both federal law (FDCA Section 503A) and Illinois state pharmacy regulations enforced by the Illinois Department of Financial and Professional Regulation (IDFPR).

Pricing: Compounded tirzepatide from Illinois-licensed 503A pharmacies averages $249 per month, representing a 76% cost reduction versus brand Mounjaro. Prices vary by dose (higher mg concentrations cost more to compound) and by pharmacy, with some telehealth-affiliated compounders offering monthly subscriptions between $199 and $399.

Legal status: The FDA's shortage list for tirzepatide, which previously permitted 503A compounding under shortage provisions, has fluctuated. As of early 2026, compounding pharmacies in Illinois continue to dispense tirzepatide under 503A rules when holding a valid patient-specific prescription. Illinois does not have state-level restrictions beyond standard IDFPR compounding regulations that prohibit compounding.

Patients considering compounded tirzepatide should verify:

• The pharmacy holds an active Illinois compounding license
• The pharmacy uses USP 797 sterile compounding standards
• The tirzepatide source material has a Certificate of Analysis from an FDA-registered facility
• The prescribing provider has conducted appropriate metabolic evaluation

A 2024 analysis published in Obesity found that patients switching from brand GLP-1 RAs to compounded versions reported similar self-reported efficacy but noted variability in injection-site reactions and dose consistency 5.

Telehealth Access to Mounjaro in Illinois

Illinois permits telehealth prescribing of Mounjaro without requiring an in-person visit for the initial prescription. The Illinois Telehealth Act, expanded during 2020-2021 and made permanent in subsequent legislation, allows licensed prescribers to evaluate patients via synchronous video and prescribe controlled and non-controlled medications including tirzepatide.

Several national telehealth platforms serve Illinois patients for GLP-1/GIP agonist prescribing. These platforms typically charge a consultation fee ($99 to $199 for initial evaluation) and may partner with compounding pharmacies or help patients manage brand medication coverage.

The telehealth workflow in Illinois generally follows this sequence: video consultation with a licensed prescriber (MD, DO, NP, or PA with Illinois licensure), metabolic labs review (A1c, fasting glucose, lipid panel, hepatic function), prescription transmission to patient's preferred pharmacy, and ongoing monthly or quarterly check-ins for dose titration.

Illinois requires that the prescribing provider hold an active Illinois medical license or practice under the Interstate Medical Licensure Compact, which Illinois joined in 2018. Out-of-state telehealth companies must ensure their prescribers meet this requirement 6.

Cost Comparison: All Illinois Options Side by Side

The total monthly cost for a Mounjaro prescription in Illinois varies dramatically depending on the access pathway:

Brand Mounjaro, no insurance: $1,023 per month. This is the sticker price at any Illinois retail pharmacy without discount programs.

Brand Mounjaro, commercial insurance + Lilly card: $25 to $150 per month. The exact figure depends on the plan's copay/coinsurance structure and whether the savings card fully offsets the remainder.

Brand Mounjaro, Illinois Medicaid: $0 to $3 per month. Medicaid copays for preferred drugs in Illinois are capped at $3 for generic equivalents; brand specialty drugs may carry no copay at all depending on MCO contract terms.

Compounded tirzepatide (503A): $199 to $399 per month, with $249 as the median. Not covered by insurance. Paid entirely out of pocket or through HSA/FSA accounts.

Brand Mounjaro with GoodRx or similar discount: $850 to $975 per month. Discount aggregators provide modest savings (5-15%) for cash-pay patients but cannot match insurance or manufacturer programs.

For a patient with type 2 diabetes and commercial insurance in Illinois, the optimal cost strategy is: obtain PA approval, apply the Lilly savings card, and pay approximately $25 per month. For uninsured patients or those seeking weight-management prescribing outside the diabetes indication, compounded tirzepatide at $249 monthly represents the most cost-effective legal option in the state.

How to Reduce Your Mounjaro Cost in Illinois

Practical steps for Illinois residents seeking the lowest possible cost:

Step 1: Check your formulary. Call the number on your insurance card and ask specifically whether tirzepatide (Mounjaro) is covered. Ask which tier and what PA requirements exist. Request the PA criteria in writing.

Step 2: Have your provider submit PA proactively. Do not wait for a pharmacy rejection. Illinois clinics can submit electronic PA through CoverMyMeds or SureScripts before the first fill, cutting 3 to 5 days off the timeline.

Step 3: Activate the savings card. If commercially insured and approved, register at the manufacturer portal before your first fill. Provide the BIN/PCN/Group numbers to your pharmacist alongside your primary insurance card.

Step 4: Appeal denials aggressively. Illinois insurance regulations require carriers to provide a determination on internal appeals within 30 days (72 hours for urgent/expedited appeals). Cite the Endocrine Society guidelines and SURPASS trial data in your appeal letter. The Illinois Department of Insurance accepts external review requests if internal appeals are exhausted 7.

Step 5: Consider compounded tirzepatide if brand access fails. Verify pharmacy licensure through the IDFPR online license lookup tool. Ask for third-party potency testing results.

According to the FDA's prescribing information for Mounjaro, the recommended starting dose is 2.5 mg once weekly for 4 weeks, titrating to 5 mg and potentially higher in 2.5 mg increments at minimum 4-week intervals based on glycemic response and tolerability 4. Starting at a lower dose does not reduce monthly cost for brand Mounjaro, but it does mean patients can assess tolerability before committing to ongoing medication expense.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, noted in a 2023 Diabetes Care editorial: "The financial toxicity of incretin therapies remains a primary driver of discontinuation, and we must acknowledge that even effective medications fail when patients cannot afford sustained access" 8.